Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioblastoma 1Astrocytoma 1

Interventions

pembrolizumab 2fludarabine 2daratumumab 2Temozolomide 2Radiation 2vocimagene amiretrorepvec 1reducing agent and tunicamycin-responsive protein, human 1pelcitoclax 1olutasidenib 1irinotecan sucrosofate 1epacadostat 1ebselen 1dexamethasone acetate 1dexamethasone 21-phosphate 1decitabine and cedazuridine drug combination 1carfilzomib 1balstilimab 1auricularum 1Vorinostat 1Transurethral Resection of Prostate 1Surveys and Questionnaires 1Specimen Handling 1Radiotherapy 1Radiofrequency Ablation 1Pluvicto 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Kidney Transplantation 1Irinotecan 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × vocimagene amiretrorepvec × 30 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡